The primary diagnosis of Bipolar I Disorder is based on the following:
Symptoms consistent with manic or mixed episodes.
Significant change in mood or behavior.
Trouble falling out of sleep or waking up suddenly.
A history of substance abuse or dependency.
A history of mood or behavior problems.
Difficulty concentrating.
In general, Bipolar I Disorder can be treated using medications. The main medications used in Bipolar I Disorder are atypical antipsychotics (such as olanzapine, risperidone, divalproex, lurasidone, fluoxetine, memantine, quetiapine, risperidone, and risperidone HCl), lithium, and valproate. The majority of medications that are used for Bipolar I Disorder are atypical antipsychotics (such as olanzapine, risperidone, divalproex, lurasidone, fluoxetine, memantine, quetiapine, risperidone, and risperidone HCl). These medications are also approved for use in other conditions, but are not approved for use in bipolar disorder. Commonly used medications for Bipolar I Disorder include:
Olanzapine (Zyprexa)
Risperidone (Risperdal)
Sertraline (Zoloft)
Tricyclic antidepressants (TCAs)
Clozapine (Clozaril)
Pimozide (Pimozide HCl)
Aripiprazole (Abilify)
It is important to note that this information is for educational purposes only and does not constitute medical advice. Consultation with a healthcare professional is recommended for the best possible care for your individual circumstances.
Bipolar I Disorder is divided into two main groups:
Depressive Disorder(also known as manic or mixed episodes)
Obsessive-Compulsive Disorder (OCD)(also known as obsessions and compulsions)
Panic Disorder(also known as p.o.
The Food and Drug Administration has issued a warning to Eli Lilly and Co., the maker of olanzapine, and to the European Medicines Agency, concerning serious adverse events involving olanzapine and olanzapine-induced weight gain. The warning also addresses the risks associated with the use of olanzapine for treatment of bipolar disorder. The FDA has issued a nationwide recall for olanzapine, which has been on the market since November 2023. The warning comes after Eli Lilly’s olanzapine, marketed under the brand name Zyprexa, was found to contain high levels of tetracycline, a compound that is believed to stimulate muscle growth in some patients with schizophrenia and bipolar disorder.
Olanzapine (Zyprexa®) is a prescription drug used to treat olanzapine-induced weight gain. (Photo by Flickr user, CC BY-SA 3.0)Antidepressants for Depression (Zoloft®)Antidepressants used for treating depression and other conditions are used to treat depression and are available by prescription only. They do not have the same risks and side effects as other medications. Some of the most common antidepressants include:
Overview
Olanzapine Information
Zyprexa Information
Comparative Analysis
Olanzapine Prescription Information
Zyprexa Prescription Information
Olanzapine Side Effects
Zyprexa Side Effects
Olanzapine Reviews
For more information on this topic, talk to your healthcare provider or contact the manufacturer directly. They will help you manage your medication more effectively.
This page contains advertisement content, which is created to support our work and services. The ad is intended to serve as a resource and does not constitute medical advice. Our mission is to provide high-quality, accessible medical information. The information in this page is general in nature and does not constitute medical advice. Our primary aim is to be a resource, not a medical device. We cannot be held responsible for the consequences of any use of any medical information or service.
Consumer comments on this page may be submitted to the manufacturer's product page. Comments may be removed by a page of the product's page. The manufacturer's website will not display the comments.
This page contains advertisements for products that may be available for purchase. If you would like to know more information about any of the products, talk to your healthcare provider or a pharmacist.
If you would like information about the product or a consumer complaint, talk to your healthcare provider.
Overview
Efficacy of aripiprazole and olanzapine as first-line therapy for acute bipolar disorder has been evaluated in two placebo-controlled trials in the adjuvant setting. The trial was a double-blind, placebo-controlled trial to evaluate the efficacy of olanzapine alone or with lithium or valproate and placebo as first-line therapy in patients with bipolar I disorder and depression.
Aripiprazole was also evaluated in a randomized, double-blind trial in the adjuvant setting to evaluate the efficacy of olanzapine alone or with lithium or valproate and placebo as first-line therapy in patients with acute bipolar I disorder and depression.
Zyprexa was also evaluated in a randomized, double-blind, placebo-controlled trial in the adjuvant setting to evaluate the efficacy of olanzapine alone or with lithium or valproate and placebo as first-line therapy in patients with acute bipolar I disorder and depression.
Olanzapine was evaluated in a randomized, double-blind, placebo-controlled trial in the adjuvant setting to evaluate the efficacy of olanzapine alone or with lithium or valproate and placebo as first-line therapy in patients with acute bipolar I disorder and depression.
In addition, olanzapine was evaluated in a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of olanzapine alone or with lithium or valproate and placebo as first-line therapy in patients with bipolar I disorder and depression.
The primary endpoint was change from baseline to the end of the trial. The secondary endpoints included change from baseline to week 48, change from week 48 to baseline, changes from week 48 to week 72, and changes from week 72 to week 24, whichever is greater.
Additional Information
All treatment regimens were evaluated in a similar manner and as planned, the trial was randomized to receive either olanzapine alone or olanzapine as first-line therapy for acute bipolar I disorder.
Olanzapine, as first-line therapy for acute bipolar I disorder, was evaluated for safety as an adjunct to lithium or valproate in a randomized, double-blind, placebo-controlled trial in the adjuvant setting.
Aripiprazole was evaluated in a randomized, double-blind, placebo-controlled trial in the adjuvant setting to evaluate the efficacy of olanzapine alone or with lithium or valproate and placebo as first-line therapy in patients with acute bipolar I disorder and depression.
Olanzapine was evaluated in a randomized, double-blind, placebo-controlled trial in the adjvant setting to evaluate the efficacy of olanzapine alone or with lithium or valproate and placebo as first-line therapy in patients with acute bipolar I disorder and depression.
In addition, olanzapine was evaluated in a randomized, double-blind, placebo-controlled trial in the adjvant setting to evaluate the efficacy of olanzapine alone or with lithium or valproate and placebo as first-line therapy in patients with acute bipolar I disorder and depression.
All treatments were administered orally at the same dose, once per day, using a standardized protocol of administration. The dose was adjusted according to response (defined as improvement from baseline in the investigator-assessed score on the Hamilton Rating Scale for Depression) and the change from baseline to week 48 as indicated by the investigator.
All patients were monitored and assessed for clinical response and treatment discontinuation. There were no significant differences between the groups in terms of clinical efficacy or safety.
Drug-drug interactions
Aripiprazole and olanzapine had significant drug interactions with at least one drug. The mean (95% confidence interval) ICI for drug was 0.025 (0.01–0.25) mg/day, for olanzapine (mean (95% CI) 0.03 (0.00–0.07)) and for clozapine (mean (95% CI) 0.03 (0.00–0.07)) in the dose-adjusted combination of azapiron (mean (95% CI) 0.04 (0.00-0.08)) and quinidine (mean (95% CI) 0.08 (0.00-0.
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
HealthylifeHealthylife is a brand name for Olanzapine, a medication used to treat schizophrenia, bipolar disorder and major depressive disorder in adults and adolescents aged 12 years and older. Healthylife contains the active ingredient Olanzapine, which belongs to a class of drugs called atypical antipsychotics. It is primarily indicated for the treatment of schizophrenia in adults and the maintenance of improvement in symptoms in adolescents when started in low doses. Healthylife has been shown to be effective in treating both acute manic and depressive episodes in patients with bipolar disorder. In clinical trials, Healthylife has been shown to be well-tolerated with a relatively high rate of side effects. Healthylife may also be used for the treatment of major depressive disorder in adults and adolescents aged 12 years and over.
This medication is available by prescription only and is taken orally as needed, usually at least 30 minutes before sexual activity. If you are experiencing sexual dysfunction, you should contact your doctor.
When product has been supplied with a generic version, Healthylife is available as the generic name. In addition, Healthylife contains the active ingredient Olanzapine, which belongs to a class of drugs called atypical antipsychotics. It is primarily indicated for the treatment of schizophrenia, bipolar disorder and major depressive disorder in adults and adolescents aged 12 years and over.
Healthylife is not for daily use. If you feel dizzy, drowsy, have PARKie’s disease, urinary retention, urinary incontinence or urinary symptoms such as difficulty passing urine, take other medications, including supplements, speak to your doctor before using this product.
If you feel dizzy, drowsy, have PARKie’s disease, urinary retention, urinary symptoms such as difficulty passing urine, take other medications, including supplements, speak to your doctor before using this product.
Healthylife is available as the generic name.
The first year of the schizophrenia treatment plan of Zyprexa has been approved, with a year of full prescribing coverage. Since then, the treatment plan has provided coverage for the following conditions: the use of the antipsychotic drug atypidine and other related drugs, a change in the form of the medication or drug from one dosage form to another, and an increase in the frequency of patients taking these medications atypidine and other related drugs.
The first year of the treatment plan of Zyprexa has been approved, with a year of full prescribing coverage. The most common of these conditions, and Zyprexa’s use in treating this condition, has been treated with a single dose of Zyprexa.
Since Zyprexa is a brand-name drug, it has been approved for use in treating this condition. This is because it has been approved for treating this condition on the basis of evidence of the drug’s effectiveness, safety, and low risk of addiction. There has been no other treatment for this condition in the 12 months before the drug was approved for use in treating this condition.
The most common of these conditions, and Zyprexa’s use in treating this condition has been treated with a single dose of Zyprexa.
Since Zyprexa is a brand-name drug, it has been approved for use in treating this condition on the basis of evidence of the drug’s effectiveness, safety, and low risk of addiction.
The Food and Drug Administration (FDA) approved Zyprexa (olanzapine) in September 2015 for the treatment of schizophrenia and bipolar disorder, as well as for the prevention of acute manic episodes in bipolar disorder and bipolar maintenance treatment. Zyprexa works by balancing the effects of certain neurotransmitters in the brain, such as dopamine and serotonin, in the brain, which can be beneficial for the treatment of depression and bipolar disorder.
Zyprexa is a drug that is often prescribed for patients who have certain underlying conditions. One of the common conditions that Zyprexa may be prescribed for is schizophrenia. Patients with schizophrenia are prescribed a medication called a second-generation antipsychotic drug (SGA) such as olanzapine (Zyprexa). Patients with bipolar disorder and schizophrenia should also be prescribed a second-generation antipsychotic drug called abilifyx (Budesonide), which is also a first-generation antipsychotic drug.
Stade de France Pharmacy